Tepper SJ, et al. - In these post hoc analyses of subgroups of patients with each of these characteristics in the ZOTRIP trial, zolmitriptan applied with Adhesive Dermally Applied Microarray (ADAM: an investigational system for intracutaneous drug administration) was investigated for its efficacy in treating types of migraine (those with severe headache pain, the presence of nausea, treatment ≥2 hours after migraine onset, or migraine present upon awakening) that are historically considered to be less responsive to oral medications. Researchers identified a poorer response to acute migraine treatment in correlation with factors like severe pain, delayed treatment, awakening with a headache, and the presence of nausea. Compared with participants receiving placebo, those who received ADAM zolmitriptan 3.8 mg exhibited nearly uniformly better headache responses (2-hour headache freedom and 2-hour MBS freedom) .